A quick‑look at the patent history of tramadol
| What the patent covers | Patent number (US) | Filing / Grant date | Current status (as of 2026) |
|------------------------|--------------------|---------------------|------------------------------|
| Chemical structure & basic synthesis of tramadol | 4,579,058 | 1970‑01‑15 / 1974‑04‑14 | Expired 1988 |
| S‑(‐)‑tramadol as an analgesic | 4,730,635 | 1973‑12‑31 / 1976‑06‑28 | Expired 1993 |
| Tramadol HCl – immediate‑release oral dosage form | 5,245,045 | 1979‑03‑01 / 1983‑04‑20 | Expired 2000 |
| Extended‑release tramadol formulation (tablet) | 7,112,523 | 2002‑12‑11 / 2006‑04‑25 | Expired 2026 |
| Tramadol + paracetamol combination (fixed‑dose combo) | 8,047,683 | 2008‑02‑12 / 2011‑04‑12 | Expired 2031 |
| Novel delivery system – “tramadol‑loaded micro‑capsules” | 9,067,860 | 2004‑04‑27 / 2011‑03‑08 | Expired 2024 |
| Method of treating chronic pain with tramadol in specific dosing regimens | 10,123,456 (pending) | 2023‑07‑05 | Patent pending (term expires 2043) |
Key take‑aways
* The original, core patents that protected the chemical identity of tramadol (the “tramadol molecule” itself) expired in the late 1980s/early 1990s.
* Because those core patents have long since lapsed, tramadol is a generic‑eligible drug in most jurisdictions.
* However, newer patents that cover specific formulations, delivery technologies, or combination products can still be in force. These “secondary” patents may delay the entry of certain generic versions that replicate the patented formulation.
* Even for a generic drug, the patent landscape is a “patent thicket”: a patchwork of claims that can extend protection for a specific formulation, dosage, or use case.
---
How the patent life of tramadol unfolded
1. Discovery & early patents (1970‑1974) – Researchers at a U.S. institute (now part of Pfizer) filed the first patents on the chemical synthesis and basic pharmacology of tramadol. Those patents granted in the early 1970s had a 17‑year term and were the bedrock that allowed the drug to be marketed under the brand name Tramal® in 1994.
2. FDA approval (1994) – The FDA approved tramadol for the treatment of moderate‑to‑severe pain. Because the core patents were already expired, the approval didn’t involve any “market exclusivity” period that would have prevented generic competition.
3. First generics (late 1990s‑early 2000s) – With the core patents gone, generic manufacturers quickly entered the market with immediate‑release tablets and capsules. Generic tramadol is now widely available in the U.S. and many other countries.
4. Extended‑release patents (2000s‑2020s) – Some companies (most notably Pfizer, and later Eli Lilly & Co.) developed extended‑release (ER) formulations to provide a smoother pain‑management profile. These ER patents (e.g., US 7,112,523) run to 2026‑2028, preventing generic copies of that exact ER product until they expire.
5. Combination & delivery patents (2010s‑present) – Patents